These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 24012960)

  • 1. Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin.
    Liu Y; Du F; Chen W; Yao M; Lv K; Fu P
    Exp Cell Res; 2013 Dec; 319(20):3140-9. PubMed ID: 24012960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4.
    Du F; Yu L; Wu Y; Wang S; Yao J; Zheng X; Xie S; Zhang S; Lu X; Liu Y; Chen W
    Cell Death Dis; 2019 Dec; 10(12):922. PubMed ID: 31801953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency.
    Jung HH; Lee SH; Kim JY; Ahn JS; Park YH; Im YH
    Sci Rep; 2016 Sep; 6():33035. PubMed ID: 27604655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pien Tze Huang () Overcomes Doxorubicin Resistance and Inhibits Epithelial-Mesenchymal Transition in MCF-7/ADR Cells.
    Chen X; Qi F; Shen AL; Chu JF; Sferra TJ; Chen YQ; Peng J
    Chin J Integr Med; 2019 Aug; 25(8):598-603. PubMed ID: 30132246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin signaling and epithelial-mesenchymal transition.
    Zhang B; Yang Y; Shi X; Liao W; Chen M; Cheng AS; Yan H; Fang C; Zhang S; Xu G; Shen S; Huang S; Chen G; Lv Y; Ling T; Zhang X; Wang L; Zhuge Y; Zou X
    Cancer Lett; 2015 Jan; 356(2 Pt B):704-12. PubMed ID: 25449432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DUSP4 Silencing Enhances the Sensitivity of Breast Cancer Cells to Doxorubicin through the Activation of the JNK/c-Jun Signalling Pathway.
    Al-Mutairi MS; Habashy HO
    Molecules; 2022 Sep; 27(19):. PubMed ID: 36234680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
    Balko JM; Cook RS; Vaught DB; Kuba MG; Miller TW; Bhola NE; Sanders ME; Granja-Ingram NM; Smith JJ; Meszoely IM; Salter J; Dowsett M; Stemke-Hale K; González-Angulo AM; Mills GB; Pinto JA; Gómez HL; Arteaga CL
    Nat Med; 2012 Jul; 18(7):1052-9. PubMed ID: 22683778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of SALL4 inhibits the proliferation and reverses the resistance of MCF-7/ADR cells to doxorubicin hydrochloride.
    Chen YY; Li ZZ; Ye YY; Xu F; Niu RJ; Zhang HC; Zhang YJ; Liu YB; Han BS
    BMC Mol Biol; 2016 Mar; 17():6. PubMed ID: 26935744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation.
    Gröschl B; Bettstetter M; Giedl C; Woenckhaus M; Edmonston T; Hofstädter F; Dietmaier W
    Int J Cancer; 2013 Apr; 132(7):1537-46. PubMed ID: 22965873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Roles for DUSP Family Members in Epithelial-to-Mesenchymal Transition and Cancer Stem Cell Regulation in Breast Cancer.
    Boulding T; Wu F; McCuaig R; Dunn J; Sutton CR; Hardy K; Tu W; Bullman A; Yip D; Dahlstrom JE; Rao S
    PLoS One; 2016; 11(2):e0148065. PubMed ID: 26859151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1.
    Yang X; Hu Q; Hu LX; Lin XR; Liu JQ; Lin X; Dinglin XX; Zeng JY; Hu H; Luo ML; Yao HR
    Discov Med; 2017 Sep; 24(131):75-85. PubMed ID: 28972876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transition.
    Kang X; Li M; Zhu H; Lu X; Miao J; Du S; Xia X; Guan W
    Oncotarget; 2017 Nov; 8(55):94028-94039. PubMed ID: 29212207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance.
    Tsou SH; Chen TM; Hsiao HT; Chen YH
    PLoS One; 2015; 10(1):e0116747. PubMed ID: 25635866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN.
    Wang ZX; Lu BB; Wang H; Cheng ZX; Yin YM
    Arch Med Res; 2011 May; 42(4):281-90. PubMed ID: 21820606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gain-of-function p53 mutant with 21-bp deletion confers susceptibility to multidrug resistance in MCF-7 cells.
    Tsou SH; Hou MH; Hsu LC; Chen TM; Chen YH
    Int J Mol Med; 2016 Jan; 37(1):233-42. PubMed ID: 26572087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR4 Links Glucose Metabolism and Chemotherapy Resistance in Breast Cancer.
    Xu M; Chen S; Yang W; Cheng X; Ye Y; Mao J; Wu X; Huang L; Ji J
    Cell Physiol Biochem; 2018; 47(1):151-160. PubMed ID: 29763898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miRNA expression patterns in chemoresistant breast cancer tissues.
    Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
    Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. USP37 downregulation elevates the Chemical Sensitivity of Human Breast Cancer Cells to Adriamycin.
    Qin T; Cui XY; Xiu H; Huang C; Sun ZN; Xu XM; Li LH; Yue L
    Int J Med Sci; 2021; 18(2):325-334. PubMed ID: 33390801
    [No Abstract]   [Full Text] [Related]  

  • 19. Liposomal curcumin alters chemosensitivity of breast cancer cells to Adriamycin via regulating microRNA expression.
    Zhou S; Li J; Xu H; Zhang S; Chen X; Chen W; Yang S; Zhong S; Zhao J; Tang J
    Gene; 2017 Jul; 622():1-12. PubMed ID: 28431975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells.
    De Vincenzo R; Scambia G; Benedetti Panici P; Fattorossi A; Bonanno G; Ferlini C; Isola G; Pernisco S; Mancuso S
    Int J Cancer; 1996 Nov; 68(3):340-8. PubMed ID: 8903476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.